- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07947056
A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)
A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefoonnummer: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
Studie Contact Back-up
- Naam: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefoonnummer: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
Studie Locaties
-
-
Andhra Pradesh
-
Guntur, Andhra Pradesh, Indië, 522503
- Werving
- All India Institute of Medical Sciences(AIIMS), Mangalagiri
-
Contact:
- Dr S Sathiyanarayanan, MBBS., MD
- Telefoonnummer: 08645 280021
- E-mail: sathiya@aiimsmangalagiri.edu.in
-
-
Assam
-
Guwahati, Assam, Indië, 781101
- Actief, niet wervend
- All India Institute of Medical Sciences, Guwahati
-
-
Gujarat
-
Rajkot, Gujarat, Indië, 360001
- Nog niet aan het werven
- Govt. PDU Medical College
-
Contact:
- Dr Bhoomika Patel, MBBS., MD
- Telefoonnummer: 0281 245 8337
- E-mail: doctorbhoomika@gmail.com
-
Surat, Gujarat, Indië, 395001
- Actief, niet wervend
- Govt. Medical College and NCH
-
-
Maharashtra
-
Mumbai, Maharashtra, Indië, 400008
- Werving
- Grant Govt. Medical College & Sir JJ Group of Hospitals
-
Contact:
- Dr Priti Meshram, MBBS., MD., DNB
- Telefoonnummer: 022 2373 5555
- E-mail: drpritimeshram@gmail.com
-
Nagpur, Maharashtra, Indië
- Nog niet aan het werven
- All India Institute Of Medical Sciences, Nagpur
-
Contact:
- Dr Yogesh Bahurupi, MBBS., MD
- Telefoonnummer: 0712 2352078
- E-mail: dr.yogeshab@gmail.com
-
-
Meghālaya
-
Shillong, Meghālaya, Indië, 793018
- Werving
- North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
-
Contact:
- Dr Monaliza Lyngdoh, MBBS., MD
- Telefoonnummer: 0364 2538013
- E-mail: monalizalyngdoh@gmail.com
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Indië, 110030
- Nog niet aan het werven
- National Institute of TB and Respiratory Diseases
-
Contact:
- Dr Jitendra Kumar Saini, MBBS., MD
- Telefoonnummer: 011 2651 3325
- E-mail: drsaini1973@gmail.com
-
-
Odisha
-
Bhubaneswar, Odisha, Indië, 751019
- Actief, niet wervend
- All India Institute of Medical Sciences (AIIMS), Bhubaneswar
-
Bhubaneswar, Odisha, Indië, 751001
- Actief, niet wervend
- Post Graduate Institute of Medical Education & Research, Capital Hospital
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indië, 600031
- Werving
- ICMR - National Institute for Research in Tuberculosis
-
Contact:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
- Telefoonnummer: 044 2836 9537
- E-mail: bhavani.pk@icmr.gov.in
-
Contact:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
- Telefoonnummer: 044 2836 9518
- E-mail: narendra.ng@icmr.gov.in
-
Hoofdonderzoeker:
- Dr PK Bhavani, MBBS., MPH., PGDBEME
-
Hoofdonderzoeker:
- Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
-
Onderonderzoeker:
- Dr R Balaji, MBBS., MD.,
-
-
Telangana
-
Hyderabad, Telangana, Indië, 500038
- Werving
- Govt. General and Chest Hospital, Osmania Medical College
-
Contact:
- Dr V Karthik, MBBS., MD
- Telefoonnummer: 04083814421
- E-mail: vkarthikrao19@gmail.com
-
-
Uttar Pradesh
-
Agra, Uttar Pradesh, Indië, 282002
- Werving
- Sarojini Naidu Medical College
-
Contact:
- Dr Gajendra Vikram Singh, MBBS., MD
- Telefoonnummer: 0562 2260353
- E-mail: drsinghgv@gmail.com
-
Allahābād, Uttar Pradesh, Indië, 211002
- Werving
- Moti Lal Nehru Medical College
-
Contact:
- Dr Amitabh Das Shukla, MBBS., MD
- Telefoonnummer: 0532 261 3592
- E-mail: adshukla1977@gmail.com
-
Lucknow, Uttar Pradesh, Indië, 226003
- Werving
- King George Medical University
-
Contact:
- Dr Rajiv Garg, MBBS., MD
- Telefoonnummer: 0522 2255167
- E-mail: rajivkgmc@gmail.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Individuals aged equal or above 14 years.
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Exclusion Criteria:
-
Body weight less than 30 kg in adults
-
Anti-TB treatment, >14 days for the current illness
-
Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
-
Patients with serious forms of Extra-pulmonary TB
-
HIV Patients on second line ART regimens.
-
Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities
- ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
- Serum Creatinine >1.2 mg/dl.
-
Pregnant or lactating mothers
-
Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
-
Patients with h/o of concomitant medications which may interfere with study drugs
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: 2H R25 ZE /4 H R10 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimenteel: 2 H R25 ZE/ 4 H R25 E
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol |
Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs. Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs. |
|
Experimenteel: 2 H R25 ZE L/2 H R25 E L
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin. |
Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs. |
|
Actieve vergelijker: 2 H R10 ZE /4H R10 E
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol |
Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Tijdsspanne: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of patients with grade 3 or 4 adverse drug reactions.
Tijdsspanne: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Tijdsspanne: Through treatment completion, an average of 24 weeks
|
Through treatment completion, an average of 24 weeks
|
|
|
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Tijdsspanne: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
|
|
|
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Tijdsspanne: At 1st Month
|
At 1st Month
|
|
|
The cost effectiveness of different treatment regimens
Tijdsspanne: Through treatment completion, an average of 24 weeks
|
Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB. |
Through treatment completion, an average of 24 weeks
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
- Hoofdonderzoeker: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis
Publicaties en nuttige links
Algemene publicaties
- Kannabiran BP, Arthanari J, Bhaskar A, Narayanan MKS, Inbaraj LR. Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: A systematic review & meta-analysis. Indian J Med Res. 2025 May;161(5):449-460. doi: 10.25259/IJMR_1673_2024.
- Perumal Kannabiran B, Palaniappan NA, Manoharan T, Paramasivam PK, Saini JK, Ansari MS, Jayabal L, Aggarwal AN, Garg R, Subramanyam B, Thakur D, Pantula S, P M R, Gs V, Natarajan S, Ammayappan RK, Manpreet B, Ganesan M, Angamuthu D, Chinnaiyan P, Singh M, Chandrasekaran P, Swaminathan S. Safety and Efficacy of 25 mg/kg and 35 mg/kg vs 10 mg/kg Rifampicin in Pulmonary TB: A Phase IIb Randomized Controlled Trial. Open Forum Infect Dis. 2024 Feb 2;11(3):ofae034. doi: 10.1093/ofid/ofae034. eCollection 2024 Mar.
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Luchtweginfecties
- Infecties
- Ziekten van de luchtwegen
- Longziekten
- Gram-positieve bacteriële infecties
- Bacteriële infecties
- Bacteriële infecties en mycosen
- Actinomycetales-infecties
- Mycobacterium-infecties
- Tuberculose
- Tuberculose, long
- Kwaliteit, toegang en evaluatie van de gezondheidszorg
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Therapeutica
- Evaluatiemechanismen voor gezondheidszorg
- Kwaliteit van de gezondheidszorg
- Polycyclische verbindingen
- Heterocyclische verbindingen, 4 of meer ringen
- Rifamycins
- Lactams, macrocyclisch
- Macrocyclische verbindingen
- Fluorochinolonen
- 4-quinolonen
- Chinolonen
- Chinolines
- Ofloxacine
- Epidemiologische studie -kenmerken
- Rifampicine
- Levofloxacine
- Klinische protocollen
Andere studie-ID-nummers
- 2025 011
- CTRI/2026/02/102698 (Register-ID: CLINICAL TRIALS REGISTRY - INDIA)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .